← Eichor
Study identifier: NCT06298968 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Combined Therapy Using Gemcitabine and Cisplatin Chemotherapy, Lenvatinib and Adebrelimab for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma

Condition: Intrahepatic Cholangiocarcinoma  ·  Sponsor: Nanfang Hospital, Southern Medical University

PhasePhase 2
Planned participants38
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

In this phase 2 study, the investigators aim to evaluate the efficacy and safety of combined therapy using gemcitabine and cisplatin chemotherapy, Lenvatinib and Adebrelimab for patients with advanced and unresectable intrahepatic cholangiocarcinoma

This description comes directly from the study's public registry record.

Talk to the study team

Mengya Zang  ·  86-20-62787430  ·  zangmy@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

Nanfang Hospital of Southern Medical UniversityGuangzhou, Guangdong, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06298968